Protein and mRNA expression of folic acid‑associated enzymes as biomarkers for the cytotoxicity of the thymidylate synthase‑targeted drugs, pemetrexed and S‑1, in non‑small cell lung cancer

Kimura,Madoka; Imamura,Fumio; Inoue,Takako; Nishino,Kazumi; Uchida,Junji; Kumagai,Toru; Okami,Jiro; Higasiyama,Masahiko; Kamoshida,Shingo

doi:10.3892/mco.2017.1262

Protein and mRNA expression of folic acid‑associated enzymes as biomarkers for the cytotoxicity of the thymidylate synthase‑targeted drugs, pemetrexed and S‑1, in non‑small cell lung cancer

Authors:
- Madoka Kimura
- Fumio Imamura
- Takako Inoue
- Kazumi Nishino
- Junji Uchida
- Toru Kumagai
- Jiro Okami
- Masahiko Higasiyama
- Shingo Kamoshida
View Affiliations

Affiliations: Department of Thoracic Oncology, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka 537‑8511, Japan, Department of Thoracic Surgery, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka 537‑8511, Japan, Laboratory of Pathology, Division of Medical Biophysics, Kobe University Graduate School of Health Sciences, Kobe, Hyogo 654‑0142, Japan
Published online on: May 16, 2017 https://doi.org/10.3892/mco.2017.1262
Pages: 15-23
Copyright: © Kimura et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The thymidylate synthase (TS)-targeted drugs, pemetrexed and S-1, exert an important role in advanced non-small cell lung cancer (NSCLC) treatment; folic acid‑associated enzymes are expected to behave as biomarkers, although their role has yet to be fully elucidated. In the present study, a single‑institutional prospective analysis, in which the mRNA and protein expression levels of five folic acid‑associated enzymes were evaluated with surgical specimens of NSCLC, was performed. Drug sensitivity was evaluated using a collagen gel droplet‑embedded culture drug sensitivity test (CD‑DST) in vitro. A total of 50 patients with NSCLC were enrolled, and the mRNA and protein expression levels of five enzymes were assessed in 47 and 46 patients, respectively. A significant association was identified between mRNA and protein expression in TS (r=0.6266), but the correlation between mRNA and protein expression levels for the other four enzymes was poor. TS mRNA expression was significantly higher in poorly differentiated tumors compared with moderately differentiated tumors (P=0.0399). TS protein expression was significantly higher in patients with pleural invasion or lymphatic invasion compared with those lacking them (P=0.027 and 0.030, respectively). CD‑DST revealed that none of the tumors that were sensitive to pemetrexed, but not to S‑1, were well differentiated, whereas none of the tumors that were sensitive to S‑1, but not to pemetrexed, were poorly differentiated. More prominent vascular invasion was observed in the tumors that were sensitive to S‑1. The only factors that exhibited the potential to discriminate the cytotoxicity of pemetrexed from S‑1 were tumor differentiation grade and vascular invasion.

View Figures

View References

1	Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, Gatzemeier U, Tsao TC, Pless M, Muller T, et al: Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol. 22:1589–1597. 2004. View Article : Google Scholar : PubMed/NCBI
2	Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U, Digumarti R, Zukin M, et al: Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 26:3543–3551. 2008. View Article : Google Scholar : PubMed/NCBI
3	Ciuleanu T, Brodowicz T, Zielinski C, Kim JH, Krzakowski M, Laack E, Wu YL, Bover I, Begbie S, Tzekova V, et al: Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: A randomised, double-blind, phase 3 study. Lancet. 374:1432–1440. 2009. View Article : Google Scholar : PubMed/NCBI
4	Okamoto I, Yoshioka H, Morita S, Ando M, Takeda K, Seto T, Yamamoto N, Saka H, Asami K, Hirashima T, et al: Phase III trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer: Results of a west Japan oncology group study. J Clin Oncol. 28:5240–5246. 2010. View Article : Google Scholar : PubMed/NCBI
5	Kawahara M, Furuse K, Segawa Y, Yoshimori K, Matsui K, Kudoh S, Hasegawa K and Niitani H: Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer. Br J Cancer. 85:939–943. 2001. View Article : Google Scholar : PubMed/NCBI
6	Urata Y, Okamoto I, Takeda M, Hattori Y, Okuno K, Shimada T, Kurata T, Kaneda H, Miyazaki M, Terashima M, et al: Phase 2 study of S-1 and carboplatin plus bevacizumab followed by maintenance S-1 and bevacizumab for chemotherapy-naive patients with advanced nonsquamous non-small cell lung cancer. Cancer. 119:2275–2281. 2013. View Article : Google Scholar : PubMed/NCBI
7	Wang L, Wang R, Pan Y, Sun Y, Zhang J and Chen H: The pemetrexed-containing treatments in the non-small cell lung cancer is -/low thymidylate synthase expression better than +/ high thymidylate synthase expression: A meta-analysis. BMC Cancer. 14:2052014. View Article : Google Scholar : PubMed/NCBI
8	Salonga D, Danenberg KD, Johnson M, Metzger R, Groshen S, Tsao-Wei DD, Lenz HJ, Leichman CG, Leichman L, Diasio RB, et al: Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res. 6:1322–1327. 2000.PubMed/NCBI
9	Metzger R, Danenberg K, Leichman CG, Salonga D, Schwartz EL, Wadler S, Lenz HJ, Groshen S, Leichman L and Danenberg PV: High basal level gene expression of thymidine phosphorylase (platelet-derived endothelial cell growth factor) in colorectal tumors is associated with nonresponse to 5-fluorouracil. Clin Cancer Res. 4:2371–2376. 1998.PubMed/NCBI
10	Saito S, Tsuno N, Nagawa H, Sunami E, Zhengxi J, Osada T, Kitayama J, Shibata Y, Tsuruo T and Muto T: Expression of platelet-derived endothelial cell growth factor correlates with good prognosis in patients with colorectal carcinoma. Cancer. 88:42–49. 2000. View Article : Google Scholar : PubMed/NCBI
11	Bonanomi A, Kojic D, Giger B, Rickenbach Z, Jean-Richard-Dit-Bressel L, Berger C, Niggli FK and Nadal D: Quantitative cytokine gene expression in human tonsils at excision and during histoculture assessed by standardized and calibrated real-time PCR and novel data processing. J Immunol Methods. 283:27–43. 2003. View Article : Google Scholar : PubMed/NCBI
12	Pérez S, Royo LJ, Astudillo A, Escudero D, Alvarez F, Rodríguez A, Gómez E and Otero J: Identifying the most suitable endogenous control for determining gene expression in hearts from organ donors. BMC Mol Biol. 8:1142007. View Article : Google Scholar : PubMed/NCBI
13	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T))method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
14	Kobayashi H, Tanisaka K, Doi O, Kodama K, Higashiyama M, Nakagawa H, Miyake M, Taki T, Hara S, Yasutomi M, et al: An in vitro chemosensitivity test for solid human tumors using collagen gel droplet embedded cultures. Int J Oncol. 11:449–455. 1997.PubMed/NCBI
15	Kobayashi H, Higashiyama M, Minamigawa K, Tanisaka K, Takano T, Yokouchi H, Kodama K and Hata T: Examination of in vitro chemosensitivity test using collagen gel droplet culture method with colorimetric endpoint quantification. Jpn J Cancer Res. 92:203–210. 2001. View Article : Google Scholar : PubMed/NCBI
16	Higashiyama M, Kodama K, Yokouchi H, Takami K, Nakagawa H, Imamura F, Minamigawa K and Kobayashi H: Cisplatin-based chemotherapy for postoperative recurrence in non-small cell lung cancer patients: Relation of the in vitro chemosensitive test to clinical response. Oncol Rep. 8:279–283. 2001.PubMed/NCBI
17	The Japan Lung Cancer Society, . General rule for clinical and pathological record of lung cancer. 7th. Kanehara & Co., Ltd.; Tokyo: 2010
18	Liu Q, Yu Z, Xiang Y, Wu N, Wu L, Xu B, Wang L, Yang P, Li Y and Bai L: Prognostic and predictive significance of thymidylate synthase protein expression in non-small cell lung cancer: A systematic review and meta-analysis. Cancer Biomark. 15:65–78. 2015. View Article : Google Scholar : PubMed/NCBI
19	Wang T, Pan C Chuan, Rui Yu J, Long Y, Cai X Hong, De Yin X, Hao L Qiong and Li Luo L: Association between TYMS expression and efficacy of pemetrexed-based chemotherapy in advanced non-small cell lung cancer: A meta-analysis. PLoS One. 8:e742842013. View Article : Google Scholar : PubMed/NCBI
20	Ibe T, Shimizu K, Nakano T, Kakegawa S, Kamiyoshihara M, Nakajima T, Kaira K and Takeyoshi I: High-grade neuroendocrine carcinoma of the lung shows increased thymidylate synthase expression compared to other histotypes. J Surg Oncol. 102:11–17. 2010. View Article : Google Scholar : PubMed/NCBI
21	Sasako M, Terashima M, Ichikawa W, Ochiai A, Kitada K, Kurahashi I, Sakuramoto S, Katai H, Sano T and Imamura H: Impact of the expression of thymidylate synthase and dihydropyrimidine dehydrogenase genes on survival in stage II/III gastric cancer. Gastric Cancer. 18:538–548. 2015. View Article : Google Scholar : PubMed/NCBI
22	Hou J, Lambers M, den Hamer B, den Bakker MA, Hoogsteden HC, Grosveld F, Hegmans J, Aerts J and Philipsen S: Expression profiling-based subtyping identifies novel non-small cell lung cancer subgroups and implicates putative resistance to pemetrexed therapy. J Thorac Oncol. 7:105–114. 2012. View Article : Google Scholar : PubMed/NCBI
23	Monica V, Scagliotti GV, Ceppi P, Righi L, Cambieri A, Lo Iacono M, Saviozzi S, Volante M, Novello S and Papotti M: Differential thymidylate synthase expression in different variants of large-cell carcinoma of the lung. Clin Cancer Res. 15:7547–7552. 2009. View Article : Google Scholar : PubMed/NCBI
24	Sowers R, Toguchida J, Qin J, Meyers PA, Healey JH, Huvos A, Banerjee D, Bertino JR and Gorlick R: mRNA expression levels of E2F transcription factors correlate with dihydrofolate reductase, reduced folate carrier, and thymidylate synthase mRNA expression in osteosarcoma. Mol Cancer Ther. 2:535–541. 2003.PubMed/NCBI
25	Igawa S, Ryuge S, Wada M, Otani S, Maki S, Takakura A, Katono K, Sasaki J, Sato Y and Masuda N: Pemetrexed for previously treated patients with non-small cell lung cancer and differences in efficacy according to thymidylate synthase expression. Chemotherapy. 58:313–320. 2012. View Article : Google Scholar : PubMed/NCBI
26	Takezawa K, Okamoto I, Okamoto W, Takeda M, Sakai K, Tsukioka S, Kuwata K, Yamaguchi H, Nishio K and Nakagawa K: Thymidylate synthase as a determinant of pemetrexed sensitivity in non-small cell lung cancer. Br J Cancer. 104:1594–1601. 2011. View Article : Google Scholar : PubMed/NCBI
27	Nicolson MC, Fennell DA, Ferry D, O'Byrne K, Shah R, Potter V, Skailes G, Upadhyay S, Taylor P, André V, et al: Thymidylate synthase expression and outcome of patients receiving pemetrexed for advanced nonsquamous non-small-cell lung cancer in a prospective blinded assessment phase II clinical trial. J Thorac Oncol. 8:930–939. 2013. View Article : Google Scholar : PubMed/NCBI
28	Ren DN, Kim IY, Koh SB, Chang SJ, Eom M, Yi SY, Seong SH, Kim MD, Bronner MP and Cho MY: Comparative analysis of thymidylate synthase at the protein, mRNA, and DNA levels as prognostic markers in colorectal adenocarcinoma. J Surg Oncol. 100:546–552. 2009. View Article : Google Scholar : PubMed/NCBI
29	Tanaka F, Wada H, Fukui Y and Fukushima M: Thymidylate synthase (TS) gene expression in primary lung cancer patients: A large-scale study in Japanese population. Ann Oncol. 22:1791–1797. 2011. View Article : Google Scholar : PubMed/NCBI